An exploratory phase II study of Eribulin re-challenge after short term therapy of 5-fuluorouracil for HER2-negative, advanced or recurrent breast cancer
التفاصيل البيبلوغرافية
العنوان:
An exploratory phase II study of Eribulin re-challenge after short term therapy of 5-fuluorouracil for HER2-negative, advanced or recurrent breast cancer
Background/aim In our previous study, first-line eribulin (ERI) showed 25 weeks of progression-free survival (PFS). This study investigated the efficacy and safety of ERI re-administration in metastatic breast cancer (MBC) patients. Patients and methods HER2-negative MBC patients who had never received chemotherapy for MBC received first-line ERI for 18 weeks if they did not have disease progression, and then one cycle of S-1 before ERI re-administration. Results Twelve patients received ERI re-administration. The PFS of re-administered ERI was 13 weeks. Total duration of ERI use was 30 weeks. The incidence and severity of adverse events were consistent with previous reports. Conclusion In the first-line setting, the total PFS of eribulin was extended by S-1 administration before disease progression, compared with that of our previous report.
Full Text via ClinicalKey